CTOs on the Move

Progyny

www.progyny.com

 
Progyny is a transformative fertility, family building, and women`s health benefits solution, trusted by the nation`s leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women`s health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.progyny.com
  • 1359 Broadway 2nd Floor
    New York, NY USA 10018
  • Phone: 212.888.3124

Executives

Name Title Contact Details
Melissa Cummings
 Executive Vice President, Chief Operating Officer Profile
Steven Leist
 Chief Technology Officer Profile
Caleb O'Connell
 Chief Information Security Officer Profile

Similar Companies

Cadence Human Systems

Cadence Human Systems is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mednex

Mednex is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioScience Business Solutions

BioScience Business Solutions is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Samsung BioLogics

Samsung Biologics is the most qualified worlds leading Contract Development, Manufacturing and Research Organization, committed to quality-driven development, manufacturing of biopharmaceutical products.

DiCE Molecules

At DiCE Molecules, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms.